📰 All Grades News
Page 2 - All Grades News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from All Grades. Real-time updates on events, politics, business and more.
February 13, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology...
December 19, 2022
The announcement that NYU would pause admissions to its music education program came as a shock to the whole program. Many questions remain unanswered.
August 17, 2022
Ready or not, school bells are ringing with some students across Wayne & Holmes counties already back in classrooms. Here are the start dates for 2022
July 7, 2022
We are experiencing the full range of energy comments in the U.S. these days, some true and others completely void of any facts to support their assertion. In this article, we will look at common hydrocarbon myths being circulated.
April 5, 2022
As the supply, reliability, and price of energy has become a global top-of-mind issue, America needs to evaluate how it views energy security for the future transition.
February 15, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA®...
February 15, 2022
SAN FRANCISCO, Feb. 14, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence dat...
February 14, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA®...
September 12, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA)...
August 12, 2021
KEYTRUDA Plus LENVIMA Is Now Approved for Two Types of Cancer, Including Advanced RCC Based on Phase 3 CLEARKEYNOTE-581 Trial, KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib Merck known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration has approved the combination of KEYTRUDA, Merck’s anti-PD-1 ...